Robert Cyran tells Richard Beales why Merck is spending $8.4 bln on Cubist – a biotech specializing in until recently unfashionable antibiotics.
06:06
00:41
02:25
01:26
01:25
00:56
00:47
02:18
01:27
02:36
01:28
00:40
01:20
00:41
00:28
01:22
01:03
02:09
00:58
00:53
01:26
00:40
01:03
02:29
00:57
02:22
01:22
01:08
01:01
02:59
01:49
00:49
02:23
00:50
02:26
01:53
00:45
01:09
00:55
01:27
00:41
01:20
01:18
01:03
01:01
00:27
01:15
01:30
02:37
00:40
00:40
00:30
01:15
00:17
02:26
00:47
00:28
00:52
00:33
01:05
01:52
01:36
01:46
01:23
01:07
00:55
01:41
01:04
02:26
03:03
02:30
01:49
02:14
01:27
02:03
01:21
07:58
00:29
01:08
01:21
02:36
01:46
01:02
01:28
01:57
01:03
02:00
03:34
01:30
00:51
02:02
00:51
02:07
02:05
01:36
01:23
02:26
01:11
00:28
01:38
02:14
01:18
01:09
01:23
01:26
01:35
01:07
02:52
05:07
01:11
01:01
01:42
01:55
01:29
00:59
00:49
00:57
01:41
02:09
01:36